2018 CMRC Research Conference: Register Now for ME/CFS Bristol Conference | 25 May 2018

 


Registration is now open for the 2018 UK CFS/M.E. Research Collaborative conference, which takes place at the Future Inn in Bristol on Wednesday 19 and Thursday 20 September.

CMRC Research Conference in Bristol on 19th and 20th of September at the Future Inn.

The conference aims to increase collaboration between researchers in the M.E. field and with those from other research/illness areas.

It is a fantastic opportunity for researchers and patients to network and learn more about the latest published and unpublished research, meet potential collaborators and contribute to future developments.

Registration fees for people with M.E. and their carers start from £50 for a single day’s conference pass to £250 per person (or £405 per shared room) for a two-day conference pass including drinks reception, delegates dinner and overnight accommodation.

This year the event will be open to everyone for both days (previously the second day of the event was only open to researchers) and the evening dinner on day one is also available to patients and their carers.

As the CMRC does not receive enough income to cover the costs of the conference, it is asking for this contribution, which is heavily subsidised to enable access to the conference for people affected by M.E.

Book your place now via the CMRC Eventbee page

The programme is still being finalised, but confirmed speakers include:

  • Dr Derya Unutmaz, National Institutes of Health, USA
  • Prof Alain Moreau, University of Montreal, Canada
  • Mark Jones, UCB Pharma
  • Dr Luis Nacul, London School of Hygiene and Tropical Medicine
  • Dr Eliana Lacerda, London School of Hygiene and Tropical Medicine; Chair, EUROMENE
  • Dr Elisa Oltra, Universidad Católica de Valencia
  • Cara Tomas, Newcastle University
  • Prof Eleanor Riley, University of Edinburgh
  • Prof Frances Williams, Kings College London

Research abstracts

If you are a researcher and would like to submit an abstract for presentation at the conference, the deadline for submissions is Friday, 13 July, 2018. Submitted abstracts will be subject to peer review before acceptance. For more details see the CMRC Eventbee page.

Filming

With speakers’ permission, we aim to film each presentation to broadcast live and/or upload as a recording following the conference. Please note that, due to the presentation of unpublished data, some speakers decline to be filmed. Details of livestreaming and/or filming will be made available nearer the time; keep an eye on our social media for announcements.

More information

The ME Association are members of the CMRC Executive along with Action for M.E. who also provide secretariat support. Details about the conference will be made available on our social media or you can find information on the CMRC Eventbee booking page.


May 2018

Interview with Prof Chris Ponting, the new Deputy Chair of the CMRC

Prof Chris Ponting is also Chair of Medical Bioinformatics at University of Edinburgh, and a Principal Investigator at the MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine.

What inspired you to join the CMRC?

In a word: Simon. I’ve known [blogger and M.E. advocate] Simon McGrath more than a decade longer than the 20 years or so of his M.E. I have seen him on his better days and have been unable to speak with him on his worst. I have seen M.E. steal some of life’s ordinary hope and future. Simon has so much more to give in life than M.E. allows.

Prof. Chris Ponting, Deputy Chair, CMRC.

I started off my career as a physicist but then chose, instead, to try to use biomedical research to make a difference to people. It was a constant frustration that I couldn’t help Simon, and other people with M.E. Now is my chance.

All that I have seen or heard tells me that change is desperately needed and needed fast. Time will soon tell whether the Collaborative can help catalyse change.

A window of opportunity is currently open, and we have to take advantage of it before it slams shut, before the attention of decision-makers and grant-funders naturally turns to other areas.

This opportunity has been gained by the exceptional work of many people, but in my view most specifically [Unrest director] Jennifer Brea, in challenging how society perceives M.E.

Much work behind the scenes is pushing for change, or more precisely for the funds needed to deliver the robust, well-powered biomolecular research that might overturn prejudice and generate new hypotheses.

What is your view on the PACE trial and behavioural treatments for M.E. and/or CFS?

There have been several questions that I thought worth asking of the PACE trial team. So, early in May 2017 I sent through questions focused on the revised recovery criteria, and on the unblinded nature of the trial and its subjective outcome measures. Of course, I am disappointed not to have received any response.

The reanalysis of PACE data by Wilshire et al. shows that effects of CBT and GET are more modest than previously claimed. I agree with them that even these modest effects could be an unintended consequence of the unblinded trial design

What challenges are the CMRC facing right now?

To help to win a step change in M.E. funding; to gather a team of scientists who work with people with M.E. across disciplines to produce world-class science; and to create the “intellectually generous community sharing data, best practice and technologies” (alongside the Collaborative’s other recently announced values).

Our research should be curious, inclusive, questioning and open-minded, and we need to celebrate well-reasoned and evidence-based views. We need to listen. When we don’t know, we say so.

Prof Stephen Holgate is the right person to lead this: he founded the CMRC; he is he go-to person for funders; he is inclusive and generous; he is an internationally renowned clinician scientist.

Yes, we do not agree on everything, which is to be expected among researchers: “Disagreement is something normal,” the Dalai Lama said. It is not Prof Holgate’s fault that UK funders have not (yet!) funded M.E. research adequately.